Bibliography
- JOUZEAU JY, TERLAIN B, ABID A, NÉDÉLEC, NETTER P: Cyclo-oxygenase isoenzymes - how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs (1997) 53:563–582.
- BAKHLE YS, BOTTING RM: Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflammation (1996) 5:305–323.
- HERSCHMAN HR: Prostaglandin synthase 2. Biochim. Biophys. Acta (1996) 1299:125–140.
- VANE JR, BOTTING RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. (1995) 44:1–10.
- BRIDEAU CD, KARGMAN S, LIU S et al.: A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. (1996) 45:68–75.
- MEADE EA, SMITH WL, DEWITT DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1993) 268:6610–6614.
- MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, FLOWER RJ, VANE JR: Selectivity of nonsteroidal antiin-flammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. ScL USA (1993) 90:11693–11697.
- TALLEY JJ: Selective inhibitors of cyclooxygenase–2. Exp. Opin. Ther. Patents (1997) 7(0:55–62.
- ••Review of earlier COX-2 inhibitor patents.
- PRASIT P, RIENDEAU D: Selective cyclooxygenase-2 inhibitors. Ann. Rep. Med. Chem. (1997) 32:211–220.
- ••Recent review on COX-2 inhibitors.
- REITZ DB, SEIBERT K: Selective cyclooxygenase inhibi-tors. Ann. Rep. Med. Chem. (1995) 30:179–188. Earlier review on COX-2 inhibitor.
- PENNING TD, TALLY JJ, BERTENSHAW SR et al.: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 445-(4-methylpheny1)-3-(trifluoromethyl)-1H-pyrazol-1-ylibenzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. (1997) 40:1347–1365. SAR on celecoxib.
- PRASIT P, WANG Z, BRIDEAU C et al.: The discovery of Rofecoxib, [MK-966, Vioxx®, 4-(4'-methylsulfonyl-pheny1)-3-pheny1-2(511)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. (1999) 9:1773–1778.
- ••Discovery of rofecoxib.
- CHAN CC, BRIDEAU C, CHARLESON S et al.: Rofecoxib, [Vioxx, 4-(4'-methylsulfonylpheny0-3-pheny1-2(511)-furanone]: a potent, highly specific and orally active cyclooxygenase-2 inhibitor - pharmacological and biochemical profiles. J. Pharmacol Exp. Ther. (1999) 290:551–560.
- ••Pharmacological and biochemical profiles of rofecoxib.
- LI JJ, NORTON MB, REINHARD EJ et al: Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J. Med. Chem. (1996) 39:1846–1856.
- PINTO JP, BATT DG, PITTS WJ et al.: Terphenyl cyclooxygenase-2 (COX-2) inhibitors: optimization of the central ring and o-biphenylanalogs. Bioorg. Med. Chem. Lett. (1999) 9:919–924.
- FRIESEN RW, BRIDEAU C, CHAN CC et al.: 2-Pyridiny1-3-(4-methylsulfonyflphenylpyridines: selective and orally active cyclooxygenase-2 inhibi-tors. Bioorg. Med. Chem. Lett. (1998) 8:2777–2782.
- •Discovery of a selective COX-2 inhibitor based on the pyridine template.
- GIERSE JK, HAUSER SD, CREELY DP et al: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. (1995) 305:479–484.